Eye Allergy Treatment Market

The eye allergy treatment market is anticipated to grow from US$ 4.28 billion in 2024 to US$ 5.93 billion by 2031, reflecting a CAGR of 5.9% from 2025 to 2031.

Market Insights and Analyst Perspective:

Eye allergy treatments encompass both over-the-counter and prescription medications aimed at relieving symptoms such as redness, itching, tearing, and swelling of the eyes. Commonly utilized products include antihistamine eye drops, mast cell stabilizers, and combination therapies. The main types of eye allergies include seasonal or perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and contact allergic conjunctivitis. The rising incidence of eye allergies globally, along with the accessibility of over-the-counter treatments, supports the growth of the eye allergy treatment market.

Factors Driving Growth:

Eye allergies, or allergic conjunctivitis, are triggered by allergens such as pollen, dust, pet dander, and mold. Increasing air pollution levels have led to a rise in eye allergy cases. Additionally, lifestyle changes, dietary habits, greater exposure to allergens, increased screen time causing eye strain, and heightened sensitivity to eye discomfort have all contributed to a significant increase in allergic reactions affecting the eyes among the global population.

A study titled A Contemporary Look at Allergic Conjunctivitis, published in 2020, indicates that allergic eye disease is prevalent in North America, affecting nearly 40% of the population, a figure that continues to rise. Approximately half of the US population experiencing ocular allergy symptoms seek medication for relief, yet only a small percentage utilize prescription treatments, highlighting the potential for new treatment developments.

Eye allergy treatments consist of products designed to manage and alleviate symptoms associated with eye allergies. These include over-the-counter medications and prescription drugs that address symptoms like redness, itching, tearing, and swelling. Common products include antihistamine eye drops, mast cell stabilizers, and nonsteroidal anti-inflammatory drugs. The increasing number of individuals suffering from eye allergies drives the demand for treatment options, thereby propelling market growth.

Current trends in the eye allergy treatment market include the development of combination therapies, which are expected to further enhance market growth in the future.

Strategic Insights

Report Segmentation and Scope:

The analysis of the eye allergy treatment market has been conducted by examining various segments: treatment type, indication, distribution channel, and geography. The treatment segment includes medication, allergy shots, and eye drops. The indication segment is divided into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. Distribution channels are categorized into hospital pharmacies, online pharmacies, and drug stores.

The scope of the eye allergy treatment market report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

The eye allergy treatment market is categorized by treatment into medication, allergy shots, and eye drops. The eye drops segment accounted for a significant market share in 2022 and is projected to exhibit the highest CAGR during 2022-2030.

By indication, the market is divided into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. The seasonal and perennial allergic conjunctivitis segment held a substantial market share in 2022 and is expected to register the highest CAGR from 2022 to 2030.

In terms of distribution channels, the market is segmented into hospital pharmacies, online pharmacies, and drug stores. The hospital pharmacies segment held a significant market share in 2022, while the online pharmacy segment is anticipated to achieve the highest CAGR during 2022-2030.

Regional Analysis:

The eye allergy treatment market report is primarily segmented by geography into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America held a significant market share in 2022, with the US leading the region. The growth in North America is attributed to the presence of advanced healthcare infrastructure, a strong presence of key market players, an increasing number of eye allergies and dry eye diseases, and the introduction of innovative medications. According to Baptist Health, nearly 50 million Americans suffer from some form of seasonal allergy, with about 30% of adults and 40% of children experiencing allergic reactions affecting their eyes, eyelids, and tear ducts.

Dry eye conditions can lead to eye allergies, which may subsequently result in dry eye disease. Dry eye disease is a common yet often underdiagnosed condition in the US. Data from the National Health and Wellness Survey published in 2020 indicated that 6.8% of the adult population in the US was diagnosed with dry eye. An article titled 'Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study,' published in 2019, reported that nearly 58% of individuals complained of dry eyes.

Pharmaceutical companies are enhancing access to specialized treatments, such as allergy-relieving eye drops, to broaden their market reach in the region. As of March 2022, Allergan’s LASTACAFT (alcaftadine ophthalmic solution 0.25%) became available to Americans with ocular allergies without a prescription. Following the recent FDA approval for the switch from prescription to over-the-counter, the original patented prescription-strength formulation of LASTACAFT can now be found online and in retail stores where OTC eye drops are sold. These factors are driving the growth of the eye allergy treatment market in the region.

Eye Allergy Treatment Market Report Scope

Industry Developments and Future Opportunities:

Several initiatives by market players in the global eye allergy treatment market include:

1. In September 2020, Dr Reddy's Laboratories launched an over-the-counter eye allergy drop, Olopatadine Hydrochloride Ophthalmic Solution, in the US market, indicated for temporary relief of itchy eyes due to pollen, grass, animal hair, and dander.
2. In February 2020, Alcon received FDA approval for Pataday’s once-daily and twice-daily relief formulations for over-the-counter sale in the US. The Pataday brand features the leading doctor-prescribed ingredient for eye allergy itch relief and includes the first once-daily allergy itch relief drop available without a prescription.

Competitive Landscape and Key Companies:

The forecast for the eye allergy treatment market can assist stakeholders in planning their growth strategies. Key players in the market include Bausch + Lomb, Alcon, AbbVie, Johnson & Johnson, Akorn Inc., Nicox, Santen Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, and Sun Pharmaceutical Industries Ltd. These companies are focused on launching innovative products, enhancing existing offerings, and expanding geographically to meet the increasing consumer demand globally.

This product will be delivered within 3-5 business days.